Caption Management’s Ascendis Pharma A/S ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-102,500
Closed -$21.9M 1543
2025
Q4
$21.9M Buy
102,500
+87,600
+588% +$18.1M 0.15% 156
2025
Q3
$2.96M Sell
14,900
-5,100
-26% -$951K 0.02% 674
2025
Q2
$3.45M Sell
20,000
-10,000
-33% -$1.63M 0.04% 525
2025
Q1
$4.68M Hold
30,000
0.05% 415
2024
Q4
$4.13M Buy
30,000
+17,500
+140% +$2.3M 0.04% 429
2024
Q3
$1.87M Buy
12,500
+5,400
+76% +$729K 0.03% 585
2024
Q2
$968K Sell
7,100
-42,900
-86% -$5.84M 0.01% 669
2024
Q1
$7.56M Buy
+50,000
New +$7.14M 0.11% 223
2023
Q3
Sell
-32,500
Closed -$2.9M 1262
2023
Q2
$2.9M Buy
32,500
+7,500
+30% +$653K 0.05% 411
2023
Q1
$2.68M Hold
25,000
0.05% 376
2022
Q4
$3.05M Buy
25,000
+3,000
+14% +$348K 0.05% 444
2022
Q3
$2.27M Buy
+22,000
New +$2.09M 0.03% 594
2022
Q2
Sell
-25,000
Closed -$2.93M 1437
2022
Q1
$2.93M Buy
25,000
+5,000
+25% +$579K 0.04% 608
2021
Q4
$2.69M Hold
20,000
0.03% 680
2021
Q3
$3.19M Sell
20,000
-150,300
-88% -$20.6M 0.04% 601
2021
Q2
$22.4M Buy
170,300
+131,500
+339% +$17.5M 0.29% 64
2021
Q1
$5M Buy
+38,800
New +$5.9M 0.11% 246

Other funds holding ASND

Caption Management's ASND Position: Q3 2025 in Review

Caption Management sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 6,499 shares — an estimated $1.21M sold.

Caption Management first reported a position in ASND in Q3 2019 and held it in 10 quarters. The position peaked at $6.25M in Q4 2024. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

  • Caption Management reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 6,499 Ascendis Pharma A/S shares in Q3 2025, an estimated $1.21M.
  • Caption Management first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 10 quarters.
  • Caption Management's Ascendis Pharma A/S position peaked at $6.25M in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.